First Targeted Kidney Disease Drug Approved by FDA

After decades of limited options, patients with IgA nephropathy now have access to the first treatment that targets the root cause of their disease.

The FDA approved sibeprenlimab in late 2025, bringing hope to thousands living with this progressive kidney condition.